Overview

Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purposes of this study were to assess Quality of Life (QoL) and urination urge, incontinence, and micturition frequency including nocturia after 4 and 12 weeks treatment with propiverine.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Takeda
Treatments:
Propiverine
Criteria
Inclusion Criteria:

- 1. Written informed consent. 2. At least 18 years of age. 3. Patients with complaints
of Overactive Bladder Syndrome (OAB) without urge incontinence, OAB with urge
incontinence, or with mixed urinary incontinence. 4. Patients who consult their GP or
an urologist for the first time with these complaints or who stopped their OAB
treatment since at least one month. 5. Receiving a propiverine prescription according
to the Summary of Product Characteristics (SPC).

Exclusion Criteria:

- None, as per the SPC contra-indications